Evidence map›Paper›PMID 24249730›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2013

Protective role of the neuropeptide urocortin II against experimental sepsis and leishmaniasis by direct killing of pathogens.

Jenny Campos-Salinas, Marta Caro, Antonio Cavazzuti, Irene Forte-Lago, Stephen M Beverley, Francisco O'Valle, Elena Gonzalez-Rey

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Peptides to Tackle Leishmaniasis: Current Status and Future Directions.International journal of molecular sciences · 2021
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Jenny Campos-SalinasInstitute of Parasitology and Biomedicine "López-Neyra," Spanish National Research Council, Granada 18016, Spain;
Marta Caro
Antonio Cavazzuti
Irene Forte-Lago
Stephen M Beverley
Francisco O'Valle
Elena Gonzalez-Rey
Instituto de Parasitología y Biomedicina "López - Neyra" · ESParque Tecnológico de la Salud · ESUniversidad de Sevilla · ESWashington University in St. Louis · US

Funding

GLYCOSYLATION MUTANTS OF LEISHMANIAR01AI031078 · NIAID · WASHINGTON UNIVERSITY · PI BEVERLEY, STEPHEN M · 1992 to 2019
$11.4M
NIAID NIH HHS R01 AI031078NIAID NIH HHS R01AI031078
6 · The paper itself

Abstract

We currently face an alarming resurgence in infectious diseases characterized by antimicrobial resistance and therapeutic failure. This has generated the urgent need of developing new therapeutic approaches that include agents with nontraditional modes of action. A recent interest focused on approaches based on our natural immune defenses, especially on peptides that combine innate antimicrobial activity against diverse pathogens and immunoregulatory functions. In this study, to our knowledge, we describe for the first time the antimicrobial activity of the neuropeptide urocortin II (UCNII) against a panel of Gram-positive and Gram-negative bacteria and tropical parasites of the genus Leishmania. Importantly, this cytotoxicity was selective for pathogens, because UCNII did not affect mammalian cell viability. Structurally, UCNII has a cationic and amphipathic design that resembles antimicrobial peptides. Using mutants and UCNII fragments, we determined the structural requirements for the interaction between the peptide and the surface of pathogen. Following its binding to pathogen, UCNII caused cell death through different membrane-disrupting mechanisms that involve aggregation and membrane depolarization in bacteria and pore formation in Leishmania. Noteworthily, UCNII killed the infective form of Leishmania major even inside the infected macrophages. Consequently, UCNII prevented mortality caused by polymicrobial sepsis and ameliorated pathological signs of cutaneous leishmaniasis. Besides its presence in body physical and mucosal barriers, we found that innate immune cells produce UCNII in response to infections. Therefore, UCNII could be considered as an ancient highly-conserved host peptide involved in the natural antimicrobial defense and emerge as an attractive alternative to current treatments for microbial disorders with associated drug resistances.

Indexed as

Amino Acid SequenceAnimalsCell MembraneCorticotropin-Releasing HormoneDrug Evaluation, PreclinicalEscherichia coliFemaleHumansHydrogen BondingImmunity, InnateIntestinal PerforationLeishmaniaLeishmaniasis, CutaneousLipopolysaccharidesMacrophagesMembrane PotentialsCorticotropin-Releasing HormoneLipopolysaccharidesPeptide FragmentsUCN2 protein, humanUCN protein, humanUrocortins

Identifiers

PMID24249730
PMCPMC3953160
OpenAlexW2112557315

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.